In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

The PFS benefit for ENHERTU plus pertuzumab versus THP was ... around two years after initiating standard-of-care first-line treatment. With a median progression-free survival of more than three ...

Grade 3 or higher treatment related adverse events (TEAEs) occurred in 54.9% of patients in the ENHERTU plus pertuzumab arm and 52.4% of patients in the THP arm. The most common grade 3 or higher ...

Enhertu, also known as trastuzumab deruxtecan, costs around £10,000 per patient per month in the US but the NHS can negotiate lower drug prices. Given as an infusion, it is a treatment for ...

Treatment, approved for several types of breast cancer, garners $3.8b sales last year In results reported at the meeting on Monday, patients who got Enhertu in combination with a standard medicine ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

The study revealed that ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% compared to the standard treatment of a taxane with trastuzumab and pertuzumab (THP).